BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Allegro Diagnostics Appoints Clinical and Scientific Advisory Board Comprised of Experts in Pulmonology, Lung Cancer and Molecular Diagnostics


6/26/2012 12:49:02 PM

Maynard, Mass., June 26, 2012 – Allegro Diagnostics today announced the formation of its Clinical and Scientific Advisory Board. Allegro has developed a molecular testing platform that utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer.

“Our advisory board is comprised of some of the most respected and prolific clinicians, researchers and pioneers in the fields of pulmonary medicine, lung cancer and cancer diagnostics,” said Michael D. Webb, President and Chief Executive Officer of Allegro Diagnostics. “These individuals will play a central role in advising Allegro on its research and development efforts, as well as on the product development strategy for the BronchoGen™ genomic test, which is approaching commercialization.”

The members of the advisory board are:

Jerome Brody, M.D., Professor of Medicine and Director of the Pulmonary Center at the Boston University School of Medicine – Dr. Brody has extensive experience in pulmonary and gene expression research and his research interests include gene expression in smokers and non-smokers, as well as the effects of smoking on airway epithelial cells.

Armin Ernst, M.D.,M.H.C.M., Professor of Medicine at Tufts School of Medicine and Chief of the Division of Pulmonary, Critical Care and Sleep Medicine at St. Elizabeth’s Medical Center – Dr. Ernst’s clinical interests include interventional pulmonology and new technology development to treat chest disease and lung cancer.

J. Scott Ferguson, M.D., Associate Professor, University of Wisconsin School of Medicine and Public Health – Dr. Ferguson is a pulmonary and critical care medicine physician with UW Health, and serves as director of the UW Health Interventional Pulmonology Program, where he is involved with using advanced diagnostics and procedures to evaluate, stage and ultimately treat pulmonary cancers.

Gerard Silvestri, M.D., Professor, Division of Pulmonary and Critical Care Medicine at the Medical University of South Carolina – Dr. Silvestri’s clinical interests include lung cancer and interventional pulmonary medicine.

Avrum Spira, M.D., M.Sc., Alexander Graham Bell Professor in Health Care Entrepreneurship and Chief of the Division of Computational Biomedicine at the Boston University School of Medicine – Dr. Spira is an attending physician with the Pulmonary/Critical Care Interventional service at Boston Medical Center, where his research is focused on applying high-throughput genomic and bioinformatics tools to the translational study of lung cancer and emphysema.

Anil Vachani, M.D., Assistant Professor of Medicine, Pulmonary, Allergy and Critical Care Division at the University of Pennsylvania School of Medicine – Dr. Vachani’s research is focused on the detection of lung cancer and mesothelioma blood biomarkers through the use of novel proteomic and genomic technologies, as well as on the molecular epidemiology of lung cancer.

About the Allegro Platform

Allegro Diagnostics’ molecular testing platform utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer. The “field of injury” principle on which the platform is based refers to the common molecular response that occurs throughout the respiratory tract in current and former smokers with lung cancer. These changes can be detected in a gene expression signature from non-malignant airway cells and indicate the presence of malignancy remotely in the lung. Allegro has applied this platform to generate multiple product candidates.

About Allegro Diagnostics

Allegro Diagnostics is a molecular diagnostics company focused on the development and commercialization of innovative genomic tests for the diagnosis, staging and informed treatment of lung cancer and other lung diseases. Allegro has developed a molecular testing platform that utilizes a genomic biomarker to detect early signs of lung cancer in current and former smokers. The company’s lead product is the BronchoGen™ genomic test for use in combination with standard bronchoscopy for the diagnosis of lung cancer. www.allegrodx.com

Contact

Jennifer Conrad

MacDougall Biomedical Communications

jconrad@macbiocom.com

(781) 235-3060


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->